| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
N‑Methyl‑DL‑valine hydrochloride does not have a specific biological receptor target. It is a valine analogue that serves as a chiral building block in asymmetric synthesis and peptide synthesis. Its N‑methylation modifies the properties of peptides, potentially affecting their hydrophobicity, stability, and cell permeability. The compound is involved in the modification of MMAF, increasing cell permeability.
|
|---|---|
| ln Vitro |
In vitro, N‑Methyl‑DL‑valine hydrochloride is metabolized to cysteine, alanine, tyrosine, tryptophan, citric acid, and succinic acid in the sprout. It serves as a building block in peptide synthesis, where its N‑methylation can modify the properties of the resulting peptides. The compound is involved in the hydrophobic functionalization of MMAF, increasing cell permeability.
|
| ln Vivo |
Specific in vivo activity data for N‑Methyl‑DL‑valine hydrochloride are not extensively detailed in available sources. As a valine derivative, it may be incorporated into metabolic pathways, but its primary use is as a research chemical and building block rather than as a pharmacologically active compound.
|
| Enzyme Assay |
Non‑cellular assays for N‑Methyl‑DL‑valine hydrochloride are not typically performed as it is a building block rather than a bioactive compound. Its identity and purity can be confirmed by analytical techniques such as HPLC, NMR, and mass spectrometry. Its role in peptide synthesis can be assessed by monitoring peptide coupling reactions.
|
| Cell Assay |
In vitro cellular assays for N‑Methyl‑DL‑valine hydrochloride are not typically performed as it is primarily used as a chemical building block. When incorporated into peptides or drug conjugates, its effects on cell permeability and activity can be assessed in cell‑based assays.
|
| Animal Protocol |
In vivo animal experiments for N‑Methyl‑DL‑valine hydrochloride are not typically conducted as it is a research chemical rather than a pharmacologically active compound. When incorporated into drug conjugates such as MMAF derivatives, the conjugates would be evaluated in animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for N‑Methyl‑DL‑valine hydrochloride are not extensively detailed in available sources. The compound has a molecular weight of 167.63 and a molecular formula of C6H14ClNO2. It is typically stored at -20°C in a sealed container, away from moisture. In solvent, it is stable at -80°C for 6 months or at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Toxicological data for N‑Methyl‑DL‑valine hydrochloride are not extensively detailed in available sources. As a valine derivative, it is expected to have low toxicity, but comprehensive toxicological profiling is not available. It is intended for research use only and not for human consumption. Standard safety precautions for handling amino acid derivatives should be followed.
|
| References |
|
| Additional Infomation |
N‑Methyl‑DL‑valine hydrochloride is a valine derivative with a molecular formula of C6H14ClNO2 and a molecular weight of 167.63. It is metabolized to various amino acids and organic acids. It is involved in the modification of MMAF, an anti‑tubulin agent, making it hydrophobic and increasing cell permeability. It serves as a building block in peptide synthesis. It is supplied for research purposes only.
|
| Molecular Formula |
C6H14CLNO2
|
|---|---|
| Related CAS # |
N-Methyl-DL-valine;2566-32-7
|
| Appearance |
White to off-white solid-liquid Mixture
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~125 mg/mL (~745.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
